metabolic engineering strategy for BC-EVs with a tumor-targeting reactive oxygen species (ROS)-responsive micelle probe. These smart probes specifically accumulate in bladder tumors and release azide-choline in response to the oxidative microenvironment, covalently incorporating azide moieties into nascent BC-EV membranes. Upon secretion into urine, these chemically tagged EVs are selectively enriched for precise BC diagnosis via bioorthogonal click chemistry, thereby effectively eliminating background interference. Crucially, this platform is able to distinguish nonmuscle-invasive BC from muscle-invasive BC based on the profiled biomarkers. This metabolic programming strategy can be extended to other diseases by simply changing the targeting and recognition moieties.
Wei et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: